Amarin Corporation plc

NasdaqGM:AMRN Stock Report

Market Cap: US$365.2m

Amarin Future Growth

Future criteria checks 4/6

Amarin is forecast to grow earnings and revenue by 51.2% and 10.1% per annum respectively. EPS is expected to grow by 50.8% per annum. Return on equity is forecast to be -13.3% in 3 years.

Key information

51.2%

Earnings growth rate

50.8%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate10.1%
Future return on equity-13.3%
Analyst coverage

Low

Last updated19 Mar 2024

Recent future growth updates

Recent updates

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Amarin: Sarissa Is Giving Me Hope Again

Jan 15

Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified

Jan 03
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified

Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)

Nov 19
Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)

Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel

Sep 27
Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel

We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth

Jul 18
We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth

Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?

Nov 11
Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?

Amarin gains as activist Sarissa starts process for special meeting to replace some board members

Oct 11

Amarin down 21% on higher than normal daily volume

Aug 22

For Amarin, Something Wishful This Way Comes

Aug 14

Amarin Q2 2022 Earnings Preview

Aug 02

HLS Therapeutics gets reimbursement for Vascepa in Ontario

Jul 25

Amarin's Vazkepa medicine gets final guidance from UK body for reimbursement and use

Jul 13

Amarin extends losses after Stat report on cardiovascular therapy

Jun 30

Amarin: Alex Denner, Health Net, Statin Combo, And Signs Of Better Times

Apr 19

Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation

Feb 23
Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation

Amarin: Revisiting Old Battles Lost

Feb 02

Earnings and Revenue Growth Forecasts

NasdaqGM:AMRN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263026N/A1073
12/31/2025233-52N/A664
12/31/2024224-6121145
12/31/2023307-5967N/A
9/30/2023322-5289N/A
6/30/2023346-38-17-16N/A
3/31/2023361-91-89-88N/A
12/31/2022369-106-181-180N/A
9/30/2022423-92-210-210N/A
6/30/2022476-100-196-196N/A
3/31/2022536-22-147-147N/A
12/31/20215838-67-67N/A
9/30/2021606-2-77-77N/A
6/30/20216204-61-61N/A
3/31/20216011-45-45N/A
12/31/2020614-18-22-22N/A
9/30/2020590-1678N/A
6/30/2020546-131719N/A
3/31/2020511-193033N/A
12/31/2019430-23-12-9N/A
9/30/2019364-63-35-33N/A
6/30/2019307-84-83-83N/A
3/31/2019259-117-123-123N/A
12/31/2018229-116-95-95N/A
9/30/2018206-105-65-65N/A
6/30/2018198-92-43-43N/A
3/31/2018190-71-29-29N/A
12/31/2017181-68-33-33N/A
9/30/2017166-73N/A-50N/A
6/30/2017151-78N/A-62N/A
3/31/2017139-78N/A-61N/A
12/31/2016130-86N/A-72N/A
9/30/2016118-81N/A-76N/A
6/30/2016107-97N/A-80N/A
3/31/201691-147N/A-96N/A
12/31/201582-149N/A-84N/A
9/30/201572-147N/A-74N/A
6/30/201564-141N/A-72N/A
3/31/201559-62N/A-57N/A
12/31/201454-56N/A-75N/A
9/30/201448-52N/A-92N/A
6/30/201442-75N/A-117N/A
3/31/201435-130N/A-158N/A
12/31/201326-166N/A-190N/A
9/30/201316-161N/A-201N/A
6/30/20138-139N/A-196N/A
3/31/20132-153N/A-164N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: AMRN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AMRN is expected to become profitable in the next 3 years.

Revenue vs Market: AMRN's revenue (10.1% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: AMRN's revenue (10.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AMRN is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.